|
Fiscal Period: December
|
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
Capitalization1 |
3 671 | 1 731 | 1 638 | 1 064 | 1 653 | 879 |
Enterprise Value (EV)1 |
11 472 | 9 056 | 8 786 | 8 099 | 8 836 | 7 691 |
P/E ratio |
-1,10x | -0,85x | -1,59x | -2,50x | 9,11x | -1,43x |
Yield |
- | - | - | - | - | - |
Capitalization / Revenue |
0,92x | 0,50x | 0,56x | 0,36x | 0,57x | 0,29x |
EV / Revenue |
2,86x | 2,61x | 2,98x | 2,78x | 3,04x | 2,57x |
EV / EBITDA |
19,2x | 12,1x | 13,8x | 12,1x | 11,2x | 8,72x |
Enterprise Value (EV) / FCF |
8,39x | 6,64x | 17,8x | 40,0x | 27,5x | 10,1x |
FCF Yield |
11,9% | 15,0% | 5,61% | 2,50% | 3,64% | 9,92% |
Price to Book |
1,36x | 3,57x | -3,29x | -1,23x | -2,55x | -0,71x |
Nbr of stocks (in thousands) |
222 877 | 223 313 | 224 345 | 226 776 | 230 292 | 233 671 |
Reference price (USD) |
16,5 | 7,75 | 7,30 | 4,69 | 7,18 | 3,76 |
Announcement Date |
03/01/2017 | 02/27/2018 | 02/28/2019 | 02/26/2020 | 02/26/2021 | 03/01/2022 |
1 USD in Million |
|
|
Income Statement Evolution (Annual data) |
|
Fiscal Period: December
|
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
Net sales1 |
4 010 | 3 469 | 2 947 | 2 914 | 2 903 | 2 993 |
EBITDA1 |
596 | 745 | 638 | 669 | 791 | 882 |
Operating profit (EBIT)1 |
455 | 630 | 544 | 588 | 692 | 793 |
Operating Margin |
11,3% | 18,2% | 18,5% | 20,2% | 23,8% | 26,5% |
Pre-Tax Profit (EBT)1 |
-3 924 | -1 483 | -939 | -345 | -26,5 | -547 |
Net income1 |
-3 347 | -2 035 | -1 031 | -423 | 184 | -613 |
Net margin |
-83,5% | -58,7% | -35,0% | -14,5% | 6,34% | -20,5% |
EPS2 |
-15,0 | -9,12 | -4,61 | -1,87 | 0,79 | -2,63 |
Free Cash Flow1 |
1 367 | 1 363 | 493 | 202 | 321 | 763 |
FCF margin |
34,1% | 39,3% | 16,7% | 6,95% | 11,1% | 25,5% |
FCF Conversion |
229% | 183% | 77,2% | 30,3% | 40,6% | 86,5% |
Dividend per Share |
- | - | - | - | - | - |
Announcement Date |
03/01/2017 | 02/27/2018 | 02/28/2019 | 02/26/2020 | 02/26/2021 | 03/01/2022 |
1 USD in Million 2 USD |
|
|
Income Statement Evolution (Quarterly data) |
|
Fiscal Period: December
|
2020 Q2 |
2020 Q3 |
2020 Q4 |
2021 Q1 |
2021 Q2 |
2021 Q3 |
2021 Q4 |
2022 Q1 |
2022 Q2 |
Net sales1 |
688 | 635 | 760 | 718 | 714 | 772 | 789 | 652 | 569 |
EBITDA1 |
329 | 286 | 344 | 365 | 343 | 387 | 387 | 311 | 160 |
Operating profit (EBIT)1 |
311 | 263 | 326 | 338 | 322 | 365 | 367 | 294 | 145 |
Operating Margin |
45,2% | 41,5% | 42,9% | 47,1% | 45,1% | 47,2% | 46,5% | 45,0% | 25,5% |
Pre-Tax Profit (EBT) |
25,3 | -64,8 | - | 47,8 | - | - | - | - | - |
Net income1 |
10,6 | -75,9 | 119 | 41,5 | -15,5 | -77,2 | -562 | -72,0 | -1 885 |
Net margin |
1,54% | -12,0% | 15,7% | 5,78% | -2,17% | -10,0% | -71,2% | -11,0% | -331% |
EPS |
0,05 | -0,33 | 0,51 | 0,17 | -0,04 | -0,33 | - | - | - |
Dividend per Share |
- | - | - | - | - | - | - | - | - |
Announcement Date |
08/05/2020 | 11/05/2020 | 02/25/2021 | 05/06/2021 | 08/05/2021 | 11/04/2021 | 02/28/2022 | 05/05/2022 | 08/09/2022 |
1 USD in Million |
|
|
|
Fiscal Period: December
|
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
Net Debt1 |
7 801 | 7 325 | 7 149 | 7 036 | 7 182 | 6 812 |
Net Cash position1 |
- | - | - | - | - | - |
Leverage (Debt / EBITDA) |
13,1x | 9,83x | 11,2x | 10,5x | 9,08x | 7,72x |
Free Cash Flow1 |
1 367 | 1 363 | 493 | 202 | 321 | 763 |
ROE (Net Profit / Equities) |
-74,4% | -77,4% | 14 352% | 52,8% | -32,7% | 60,2% |
Shareholders' equity1 |
4 501 | 2 631 | -7,19 | -800 | -563 | -1 019 |
ROA (Net Profit / Asset) |
1,69% | 3,04% | 3,13% | 3,76% | 4,63% | 5,50% |
Assets1 |
-198 004 | -66 944 | -33 006 | -11 234 | 3 970 | -11 155 |
Book Value Per Share2 |
12,1 | 2,17 | -2,22 | -3,82 | -2,81 | -5,32 |
Cash Flow per Share2 |
2,32 | 4,42 | 5,12 | 6,41 | 5,27 | 6,45 |
Capex1 |
139 | 126 | 86,9 | 67,7 | 72,9 | 80,7 |
Capex / Sales |
3,46% | 3,62% | 2,95% | 2,32% | 2,51% | 2,69% |
Announcement Date |
03/01/2017 | 02/27/2018 | 02/28/2019 | 02/26/2020 | 02/26/2021 | 03/01/2022 |
1 USD in Million 2 USD |
|
| |
|
|
Teva, Allergan reach $161.5 mln opioid settlement with West Virginia |
Capitalization (USD) |
23 919 814 |
Net sales (USD) |
2 993 206 000 |
Number of employees |
3 103 |
Sales / Employee (USD) |
964 617 |
Free-Float |
99,2% |
Free-Float capitalization (USD) |
23 732 806 |
Avg. Exchange 20 sessions (USD) |
91 453 |
Average Daily Capital Traded |
0,38% |
Change in Enterprise Value/EBITDA
|